Codetta Biosciences

Codetta Biosciences is a private, pre-revenue platform company founded in 2019, headquartered in Morrisville, North Carolina. The company's core innovation is the Codetta Bio Concerto™ System, a mid-plex instrument that uniquely integrates protein and nucleic acid (DNA/RNA) detection into a single, automated workflow using microbead-based capture and a proprietary 'noise-cancelling' immunoPCR technology. Targeting the translational research market across oncology, immunology, neurology, and infectious disease, Codetta aims to set a new standard for multi-omic biomarker analysis by combining the precision of digital PCR with the dynamic range of qPCR.

The Codetta Bio Concerto™ System, a harmonized multi-omic platform that integrates microbead-based target capture with digital PCR, real-time PCR, and immunoPCR to simultaneously quantify proteins, DNA, and RNA from a single sample in a 3-hour workflow. It features proprietary 'noise-cancelling' technology for high-specificity multiplexing.

Codetta competes in the life science tools and multi-omics space. Direct competitors include companies like Olink (proteomics) and Bio-Rad (dPCR) used in separate workflows, and emerging platforms seeking integrated analysis. Its main challenge is displacing entrenched, single-technology workflows with its novel combined approach.